Comparative Pharmacology
Head-to-head clinical analysis: ARYMO ER versus JOBEVNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYMO ER versus JOBEVNE.
ARYMO ER vs JOBEVNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYMO ER (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception. It also activates descending inhibitory pathways.
JOBEVNE is a monoclonal antibody that binds to and inhibits the activity of a specific cytokine receptor, reducing inflammatory signaling.
15 mg to 30 mg orally every 12 hours; titrate to effect; maximum 60 mg per dose.
100 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours in healthy adults. This extended half-life compared to immediate-release morphine (2–4 hours) allows for once-daily dosing. In elderly or hepatic/renal impairment, half-life may be prolonged up to 22 hours.
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing in most patients
Primarily renal (90%), with approximately 10% excreted unchanged in urine; the remainder as glucuronide conjugates (morphine-3-glucuronide, morphine-6-glucuronide) and minor metabolites. Biliary/fecal excretion accounts for <10%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic